-

KAIVAL BRANDS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Kaival Brands Innovations Group, Inc. - KAVL

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Kaival Brands Innovations Group, Inc. (the “Company”) (NasdaqCM: KAVL) and Delta Corp Holdings Limited. Pursuant to the terms of the agreement, shareholders of Kaival Brands will receive 1 ordinary share of a specially created holding company incorporated under the laws of the Cayman Islands, Delta Corp Holdings Limited (“Pubco”) for each share of Kaival Brands common stock they own as of the closing of the business combination. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Kaival shareholders.

If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqcm-kavl/ to learn more.

To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com.

Kahn Swick & Foti, LLC
1100 Poydras St., Suite 960
New Orleans, LA 70163

Contacts

Lewis S. Kahn (lewis.kahn@ksfcounsel.com)
855-768-1857

Industry:

Kahn Swick & Foti, LLC

NASDAQ:KAVL
Release Versions
English

Contacts

Lewis S. Kahn (lewis.kahn@ksfcounsel.com)
855-768-1857

More News From Kahn Swick & Foti, LLC

KalVista Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of KalVista Pharmaceuticals, Inc. - KALV

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of KalVista Pharmaceuticals, Inc. (NasdaqGM: KALV) to Chiesi Group. Under the terms of the proposed transaction, shareholders of KalVista will receive $27.00 in cash for each share of KalVista that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequ...

Assertio Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Assertio Holdings, Inc. - ASRT

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Assertio Holdings, Inc. (NasdaqCM: ASRT) to Garda Therapeutics. Under the terms of the proposed transaction, shareholders of Assertio will receive $18.00 per share in cash and a contingent value right. KSF is seeking to determine whether this consideration and the process that led to it are adequate,...

UniFirst Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of UniFirst Corporation - UNF

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of UniFirst Corporation (NYSE: UNF) to Cintas Corporation (NasdaqGS: CTAS). Under the terms of the proposed transaction, shareholders of UniFirst will receive $155.00 in cash and 0.7720 shares of Cintas stock for each share of UniFirst that they own. KSF is seeking to determine whether this considerati...
Back to Newsroom